Relation between severity of Alzheimer's disease and costs of caring
- PMID: 9757169
- PMCID: PMC1229640
Relation between severity of Alzheimer's disease and costs of caring
Abstract
Background: Data from the Canadian Study of Health and Aging (CSHA) were used to examine the relation between severity of Alzheimer's disease, as measured by the Mini-Mental State Examination (MMSE), and costs of caring.
Methods: The CSHA was a community-based survey of the prevalence of dementia, including subtypes such as Alzheimer's disease, among elderly Canadians. Survey subjects with a diagnosis of possible or probable Alzheimer's disease were grouped into disease severity levels of mild (MMSE score 21-26), mild to moderate (MMSE score 15-20), moderate (MMSE score 10-14) and severe (MMSE score below 10). Components of care available from the CSHA were use of nursing home care, use of medications, use of community support services by caregivers and unpaid caregiver time. Costs were calculated from a societal perspective and are expressed in 1996 Canadian dollars.
Results: The annual societal cost of care per patient increased significantly with severity of Alzheimer's disease. The cost per patient was estimated to be $9451 for mild disease, $16,054 for mild to moderate disease, $25,724 for moderate disease and $36,794 for severe disease. Institutionalization was the largest component of cost, accounting for as much as 84% of the cost for people with severe disease. For subjects living in the community, unpaid caregiver time and use of community services were the greatest components of cost and increased with disease severity.
Interpretation: The societal cost of care of Alzheimer's disease increases drastically with increasing disease severity. Institutionalization is responsible for the largest cost component.
Comment in
-
Caring for patients with Alzheimer's disease in Italy.CMAJ. 1999 Nov 30;161(11):1390, 1392. CMAJ. 1999. PMID: 10906892 Free PMC article. No abstract available.
Similar articles
-
Determinants of costs of care for patients with Alzheimer's disease.Int J Geriatr Psychiatry. 2006 May;21(5):449-59. doi: 10.1002/gps.1489. Int J Geriatr Psychiatry. 2006. PMID: 16676288
-
Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.J Alzheimers Dis. 2010;19(2):601-15. doi: 10.3233/JAD-2010-1258. J Alzheimers Dis. 2010. PMID: 20110605
-
The cost of Alzheimer's disease in managed care: a cross-sectional study.Am J Manag Care. 1999 Jul;5(7):867-77. Am J Manag Care. 1999. PMID: 10557408
-
Assessing the societal impact of acetylcholinesterase inhibitor therapies.Alzheimer Dis Assoc Disord. 1999 Nov;13 Suppl 2:S9-19. Alzheimer Dis Assoc Disord. 1999. PMID: 10622674 Review.
-
[Model of costs of care for dementia: community-dwelling vs. institutionalization].Tijdschr Gerontol Geriatr. 2000 Apr;31(2):55-61. Tijdschr Gerontol Geriatr. 2000. PMID: 10816892 Review. Dutch.
Cited by
-
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000. CNS Drugs. 2010. PMID: 20932064 Review.
-
Economic considerations in the management of Alzheimer's disease.Clin Interv Aging. 2006;1(2):143-54. doi: 10.2147/ciia.2006.1.2.143. Clin Interv Aging. 2006. PMID: 18044111 Free PMC article. Review.
-
The Neuropathological Impacts of COVID-19: Challenges and Alternative Treatment Options for Alzheimer's Like Brain Changes on Severely SARS-CoV-2 Infected Patients.Am J Alzheimers Dis Other Demen. 2023 Jan-Dec;38:15333175231214974. doi: 10.1177/15333175231214974. Am J Alzheimers Dis Other Demen. 2023. PMID: 37972355 Free PMC article. Review.
-
Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):330-6. doi: 10.1007/s00406-007-0727-1. Epub 2007 Apr 1. Eur Arch Psychiatry Clin Neurosci. 2007. PMID: 17404699
-
Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.J Alzheimers Dis. 2020;74(1):127-138. doi: 10.3233/JAD-190811. J Alzheimers Dis. 2020. PMID: 31985460 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical